Divi's Laboratories Limited vs Onesource Specialty Pharma Limited

A side-by-side comparison of Divi's Laboratories Limited (DIVISLAB) and Onesource Specialty Pharma Limited (ONESOURCE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Divi's Laboratories Limited leads DIVISLAB vs ONESOURCE on 10 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability40
  • Growth01
  • Size & financial health40

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

94.52
P/E ratio
-364.50
14.90
P/B ratio
3.04
0.32%
Dividend yield
0.00%
₹96.75
EPS
₹-6.44

Profitability

DIVISLAB takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

15.32%
Return on equity
-1.27%
20.35%
Return on capital
0.43%
32.59%
EBITDA margin
21.40%
24.32%
Net margin
-5.19%

Growth

ONESOURCE takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
231.57%
12.09%
Profit CAGR (3Y) even
—

Size & financial health

DIVISLAB takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹2.45L Cr
Market cap
₹16,154 Cr
₹10,560 Cr
Revenue
₹1,422 Cr
₹2,568 Cr
Net profit
₹-74 Cr
0.00
Debt / equity
0.22
Divi's Laboratories Limited
  • + ["Company has been maintaining a healthy dividend payout of 31.0%", "Company is almost debt free."]
  • − ["Stock is trading at 14.48 times its book value", "The company has delivered a poor sales growth of 8.7% over past five years."]
Onesource Specialty Pharma Limited
  • + ["Company has delivered good sales growth of 132.3% CAGR over last 5 years"]
  • − ["Company has a low return on equity of -22.7% over last 3 years.", "Company reported a net loss of ₹74 Cr in its latest financial year."]
Divi's Laboratories Limited full analysis Onesource Specialty Pharma Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.